Vaccine最新文献

{"title":"Comparative study on the inactivation and immunogenicity of Mycoplasma hyopneumoniae and Mycoplasma hyorhinis vaccines prepared using different inactivants.","authors":"Yanna Wei, Jia Wang, Li Wang, Beibei Liu, Ting Yuan, Yanfei Yu, Guoqing Shao, Zhixin Feng, Thandeka Ntokozo Khoza, Qiyan Xiong","doi":"10.1016/j.vaccine.2025.126766","DOIUrl":"10.1016/j.vaccine.2025.126766","url":null,"abstract":"<p><p>The present study aimed to investigate the optimal inactivants and inactivation conditions for preparing inactivated vaccines of Mycoplasma hyopneumoniae and Mycoplasma hyorhinis. Mycoplasma inactivation was performed using formaldehyde, thimerosal, β-propiolactone (BPL), and binary ethylenimine (BEI) and compared. The results showed that M. hyopneumoniae was completely inactivated when incubated with 0.01 % formaldehyde for 24 h or 0.02 % formaldehyde for 12 h at 37 °C, with 0.0008 % thimerosal for 12 h at 37 °C, with 0.02 % BPL for 24 h or 0.1 % BPL for 12 h at 4 °C, or with 0.004 % BEI for 24 h or 0.5 % BEI for 12 h at 37 °C. M. hyorhinis was completely inactivated when incubated with 0.01 % formaldehyde for 24 h or 0.02 % formaldehyde for 12 h at 37 °C, with 0.004 % thimerosal for 24 h or 0.02 % thimerosal for 12 h at 37 °C, with 0.1 % BPL for 12 h at 4 °C, or with 0.004 % BEI for 24 h or 0.5 % BEI for 12 h at 37 °C. Next, the immunogenicity of the mycoplasmas after inactivation was evaluated by immunizing BALB/c mice. Immunization of mice with a high dose (10⁶ color-changing units [CCU] per dose) of M. hyopneumoniae and M. hyorhinis vaccines inactivated with all inactivants led to high levels of serum IgG antibodies. M. hyopneumoniae vaccines inactivated with formaldehyde induced significantly higher titers of antibodies than vaccines inactivated with other inactivants, whereas M. hyorhinis vaccines inactivated with BEI induced significantly higher titers of antibodies than vaccines inactivated with thimerosal. However, in mice immunized with a low dose of mycoplasmas (10⁴ CCU per dose), only M. hyopneumoniae vaccines inactivated with formaldehyde and BEI and M. hyorhinis vaccines inactivated with formaldehyde, BPL, and BEI led to significant levels of serum IgG antibodies. Among these groups, the antibody levels in the formaldehyde-inactivated vaccine group were higher than those in the other inactivant groups. This study provides a reliable basis for inactivation during large-scale production of Mycoplasma hyopneumoniae and Mycoplasma hyorhinis inactivated vaccines.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"126766"},"PeriodicalIF":3.5,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143044001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the editor: SARS-CoV-2 vaccination in children and adolescents with neurodevelopmental or psychiatric disorders.","authors":"Arnaud Fernandez, Florence Askenazy, Susanne Thümmler","doi":"10.1016/j.vaccine.2024.126679","DOIUrl":"10.1016/j.vaccine.2024.126679","url":null,"abstract":"","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"126679"},"PeriodicalIF":3.5,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142911350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 vaccine uptake and attitudes in emerging adults with type 1 diabetes.","authors":"Colleen A Macke, Samantha A Carreon, Kishan R Desai, Charles G Minard, Sarah K Lyons, Siripoom McKay, Sridevi Devaraj, Randi Streisand, Tricia Tang, Barbara J Anderson, Marisa E Hilliard","doi":"10.1016/j.vaccine.2025.127083","DOIUrl":"10.1016/j.vaccine.2025.127083","url":null,"abstract":"<p><strong>Purpose: </strong>Adolescents and young adults have lower uptake of vaccines for preventable diseases than children and older adults. Young adults with type 1 diabetes (T1D) are at risk of complications from many vaccine-preventable illnesses. Given the elevated health risks of SARS-COV-2 infection for people with T1D, it is important to understand COVID-19 vaccination rates and attitudes. We explored vaccine uptake and characterized self-reported reasons for declining vaccination in a cohort of young adults with T1D as they were leaving pediatric care during the COVID-19 pandemic.</p><p><strong>Methods: </strong>Participants enrolled in a randomized controlled trial of a transition intervention for young adults with T1D reported COVID-19 vaccination at baseline (2/2021-6/2023). We report rates of COVID-19 vaccination in addition to demographic and medical characteristics. Participants who did not receive vaccination were asked to note the reason(s). From these qualitative responses we identified themes.</p><p><strong>Results: </strong>Of the n = 97 participants reporting vaccination status, 70.1 % reported receiving at least one COVID-19 vaccine. No demographic or medical characteristics were significantly associated with vaccination status (p ≥ 0.05). Themes of reasons for not receiving the COVID-19 vaccination included Doubt, Fear, External Factors, and Indifference.</p><p><strong>Discussion: </strong>In young adults with T1D, COVID-19 vaccine uptake is below public health targets. Addressing fears about vaccine-related effects on T1D, doubts surrounding vaccine development and efficacy, and other external factors influencing vaccination decisions may be helpful in initiating a dialogue between clinicians and young adults considering vaccination. Further investigation into attitudes about other preventative care measures in this vulnerable population is needed. Clinical trial registry site and number: ClinicalTrials.gov ID Number - NCT04247620.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"127083"},"PeriodicalIF":3.5,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13463278/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144765939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunogenicity and safety of sequential Sabin strain inactivated poliovirus vaccine from different manufacturers in infants: Randomized, blinded, controlled trial.","authors":"Lei Wang, Weixian Han, Dan Li, Siquan Wang, Zhao Jiang, Yuwei Li, Siliang Zhou, Yongli Xiong, Yanfei Chen, Lixian Wang, Yingchao Wan, Jing Li, Yeqing Tong","doi":"10.1016/j.vaccine.2025.127448","DOIUrl":"10.1016/j.vaccine.2025.127448","url":null,"abstract":"<p><strong>Objectives: </strong>The National Immunization Program allows using a different manufacturer's vaccine for follow-up doses when the same vaccine is unavailable. This study aimed to evaluate the safety and immunogenicity of administering a third dose of Sabin strain (sIPV) from a different manufacturer in infants who had previously received two doses of sIPV.</p><p><strong>Methods: </strong>This randomized, blinded, controlled trial enrolled 200 healthy infants (≤12 months) to assess the safety and immunogenicity of sequential vaccination, who were randomly assigned to receive a third dose of sIPV from either a different manufacturer (experimental group) or the same manufacturer as the first two doses (control group). The study took place in Xiaogan City, Hubei Province, China, from 20 May 2024 to 6 September 2024. Immunogenicity and safety were assessed using per-protocol and safety populations, respectively.</p><p><strong>Results: </strong>The seroconversion rates for poliovirus types 1, 2, and 3 were 79.52 %, 67.47 %, and 74.70 % in the experimental group, respectively, compared to 73.56 %, 49.43 %, and 63.22 % in the control group, with P-values of 0.360, 0.017, and 0.106, respectively. The most common systemic adverse event (AE) was fever, and no significant differences in the incidence of AEs between the two groups were observed. No serious adverse events related to vaccines were reported.</p><p><strong>Conclusion: </strong>Sequential vaccination with sIPV from different manufacturers demonstrated superior immunogenicity compared to the initial vaccine, with no significant safety differences, indicating that using vaccines from different manufacturers for sequential dosing is a feasible and effective option.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"61 ","pages":"127448"},"PeriodicalIF":3.5,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144565604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between basal humoral immunogenicity and side effects after receiving the bivalent formulation of a mRNA-based vaccine.","authors":"Laura Pighi, Gian Luca Salvagno, Giuseppe Lippi","doi":"10.1016/j.vaccine.2025.126803","DOIUrl":"10.1016/j.vaccine.2025.126803","url":null,"abstract":"","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"126803"},"PeriodicalIF":3.5,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness and budget impact analyses of the 24-valent pneumococcal conjugate vaccine in adults aged 50 and older.","authors":"Shoroq M Altawalbeh, Angela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, Lee H Harrison, William Schaffner, Richard K Zimmerman, Kenneth J Smith","doi":"10.1016/j.vaccine.2025.127433","DOIUrl":"10.1016/j.vaccine.2025.127433","url":null,"abstract":"<p><p>A 24-valent pneumococcal conjugate vaccine (PCV24) is currently in development and could potentially be used in all adults aged 50 years and older. This study evaluated risk- and age-based PCV24 use to ascertain its potential public health effects, budget impact, and cost-effectiveness. A Markov decision analysis model compared PCV24 and all currently recommended pneumococcal vaccines. Age-based vaccination could occur at age 50 or at ages 50 and 65. The analysis separately examined hypothetical cohorts of U.S. Black and non-Black individuals with and without consideration of childhood pneumococcal vaccination indirect effects, using race-specific pneumococcal disease and vaccination data. Cohorts were tracked over a lifetime horizon from both societal and healthcare perspectives. Model parameters were derived from U.S. data and parameter uncertainty was evaluated through deterministic and probabilistic sensitivity analyses. Budgetary impact of 21-valent conjugate vaccine (PCV21), PCV24, and combinations of both at different ratios was also assessed. From societal and healthcare perspectives, PCV24 prevented fewer pneumococcal disease cases and deaths but was less economically favorable than strategies using PCV21. Other vaccines were similarly less favorable than PCV21. When adding childhood vaccination indirect effects, PCV24 strategies remained unfavorable compared to PCV21 strategies. In probabilistic sensitivity analyses, PCV21 at ages 50 and 65 was preferred in 99 % of model iterations for Black cohorts and 85 % for non-Blacks at a $100,000/QALY willingness-to-pay threshold. Budget impact for PCV24 and PCV21 were not substantially different but PCV21 prevented more hospitalizations and deaths. Compared to PCV21, which is formulated solely on adult pneumococcal epidemiology, PCV24 and other childhood epidemiology-formulated vaccines were less economically favorable among adults aged 50 and older. Budget impacts of PCV21 and PCV24 use were similar.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"61 ","pages":"127433"},"PeriodicalIF":3.5,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12375138/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 vaccine attitudes, beliefs, intentions and behaviors among pregnant women within the context of dynamic national policy recommendations in Brazil, Ghana, Kenya, and Pakistan.","authors":"Jessica L Schue, Emily S Miller, Berhaun Fesshaye, Prachi Singh, Renato T Souza, Caroline Dinam Badzi, Emefa Modey Amoah, Saleem Jessani, Muhammad Asim, Ingrid Gichere, Maria Laura Costa, Jose G Cecatti, Kwasi Torpey, Sarah Saleem, Marleen Temmerman, Sami L Gottlieb, Rupali J Limaye","doi":"10.1016/j.vaccine.2025.127595","DOIUrl":"10.1016/j.vaccine.2025.127595","url":null,"abstract":"<p><strong>Introduction: </strong>There are many factors associated with maternal immunization decision making. This study aimed to describe COVID-19 vaccination attitudes, beliefs, behaviors, and intentions among pregnant women across four countries within the context of varying and changing policy recommendations related to COVID-19 vaccination for pregnant women.</p><p><strong>Methods: </strong>This cross-sectional quantitative study surveyed pregnant women in antenatal care facilities serving mostly urban or peri-urban populations in Campinas, Brazil; Accra, Ghana; Nairobi, Kenya; and Karachi, Pakistan. Potential participants were approached in clinic waiting rooms, and if eligible, enrolled after informed consent was obtained.</p><p><strong>Results: </strong>A total of 1603 women were surveyed, with 64 % overall reporting they received a COVID-19 vaccine, ranging from 46 % in Pakistan to 97 % in Brazil. Among those ever vaccinated, 15 % received a COVID-19 vaccine during pregnancy, most received only one dose during pregnancy and the majority (53 %) reported they were vaccinated in their first trimester. The top two reasons for vaccination were the same across all countries: protecting themselves and protecting their baby. Among those not vaccinated against COVID-19, the majority of participants (68 %) indicated that they did not intend to be vaccinated, and fears that the vaccine was not safe was the highest rank among all countries as the primary reason for not getting vaccinated. In adjusted models, higher disease risk perception (aOR: 1.88; CI: 1.35-2.62), higher beliefs in vaccine effectiveness for the pregnant women (aOR: 1.75; CI: 1.19-2.55), belief in the safety of the vaccine for their baby (aOR: 2.30; CI: 1.46-3.64), and believing that peers were taking the vaccine (aOR: 1.54; CI: 1.14-2.08) were associated with vaccination status. Holding views consistent with vaccine hesitancy was associated with lower odds of vaccination (aOR: 0.28; CI: 0.20-0.40).</p><p><strong>Discussion: </strong>Enhancing risk perception of COVID-19 in pregnancy, knowledge about safety and benefits of the vaccine compared to the risks, and promoting supportive environments where vaccines are perceived as normative behavior can help increase vaccine uptake among pregnant women.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"127595"},"PeriodicalIF":3.5,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144801397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring COVID-19 vaccination behavior: A cross-country study among pregnant and postpartum women in Brazil, Ghana, Kenya, and Pakistan.","authors":"Rupali J Limaye, Berhaun Fesshaye, Emily S Miller, Prachi Singh, Saleem Jessani, Muhammad Asim, Ferdinand Okwaro, Caroline Dinam Badzi, Emefa Modey Amoah, Renato T Souza, Maria Laura Costa, Sarah Saleem, Marleen Temmerman, Kwasi Torpey, Jose G Cecatti, Vanessa Brizuela, Jessica L Schue","doi":"10.1016/j.vaccine.2025.127478","DOIUrl":"10.1016/j.vaccine.2025.127478","url":null,"abstract":"<p><p>Pregnant women infected with SARS-CoV2 are more likely to be hospitalized and require ventilation, compared to non-pregnant women. Although the development of the COVID-19 vaccine was regarded as a scientific breakthrough among many, the pace of development in combination with delayed and unclear recommendations for maternal vaccination led to slower vaccine uptake among this population. We explored the decision-making process for COVID-19 vaccination among pregnant and postpartum women in four countries: Brazil, Ghana, Kenya, and Pakistan through 201 in-depth interviews. A grounded theory approach was used for analysis, and a socio-ecological framework was used to synthesize emerging themes. Four levels of influence on vaccine-related attitudes and behaviors were identified: individual, interpersonal, community, and policy. Risk perception and beliefs about vaccines safety were the primary individual-level factors identified. Risk perception of the disease was a common reason for vaccine acceptance, whereas lower risk perception emerged as a reason to not vaccinate. Vaccine safety concerns, for the pregnant woman herself, her pregnancy, and her baby were common across all countries. At the interpersonal level, the influence of the male partner and peers emerged across all countries. While participants identified the partner or spouse was most influential, they also discussed the limited impact the male partner had on decision-making, particularly in Ghana, Kenya, and Pakistan. At the community-level, healthcare providers helped in allaying vaccine safety concerns, and women looked to them for their health expertise and recommendations. At the policy-level, the requirement - real or perceived - of vaccination to access services, travel, work, and education was an important factor in all countries. Vaccine decision-making is complex, multi-faceted, and context-specific. When promoting vaccination among pregnant and postpartum women, engaging influential individuals can support the successful uptake of maternal vaccination.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"127478"},"PeriodicalIF":3.5,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144644498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 vaccine attitudes and behaviors among pregnant women in Nairobi, Kenya with diverse socio-economic and educational backgrounds.","authors":"Jessica L Schue, Ferdinand Okwaro, Ingrid Gichere, Daizy Cherono, Mandeep Sura, Emily S Miller, Berhaun Fesshaye, Prachi Singh, Grace Belayneh, Rupali J Limaye, Marleen Temmerman","doi":"10.1016/j.vaccine.2025.127480","DOIUrl":"https://doi.org/10.1016/j.vaccine.2025.127480","url":null,"abstract":"<p><strong>Introduction: </strong>Pregnant women are at increased risk of severe manifestations of COVID-19, resulting in ICU admission, mechanical ventilation, and death compared to non-pregnant women. COVID-19 vaccines were approved for use in pregnant women in early 2022 by the World Health Organization, but permissive policies toward vaccine women differed by country. As education has been associated with vaccine uptake, this study sought to examine the association between socio-economic or educational status and vaccination behaviors, including reasons for vaccination or non-vaccination among pregnant women seeking health care services in Nairobi, Kenya.</p><p><strong>Methods: </strong>This study administered a survey to pregnant women at the two referral hospitals in Nairobi: Aga Khan University Hospital (AKUH) and Pumwani Maternity Hospital (PMH).</p><p><strong>Results: </strong>A total of 400 women took the survey. Pregnant women with college level education were more likely to have been vaccinated for COVID-19 compared to pregnant women without a college education. Women registered or visiting for pregnancy and delivery care from AKUH Kenya were also more likely to be vaccinated compared to women receiving care from PMH. Despite this difference in COVID-19 vaccine uptake, women from both the hospitals had similar reasons for receiving or refusing a COVID-19 vaccine. a Our findings align with previous studies that have showed that education status correlates positively with COVID-19 vaccination among pregnant women.</p><p><strong>Discussion: </strong>To improve maternal vaccination acceptance, education status can be used as a way to segment audiences to inform messaging and other demand generation efforts.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"127480"},"PeriodicalIF":0.0,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144628467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Engaging rural and non-Hispanic Black persons in conversations about the COVID-19 vaccine: a process evaluation of a natural helper intervention.","authors":"Robin E McGee, D'Jata A Barrett, Robert A Bednarczyk, Marian Grant-Whitlock, Michelle C Kegler, Kimberly R Jacob Arriola","doi":"10.1016/j.vaccine.2025.127587","DOIUrl":"10.1016/j.vaccine.2025.127587","url":null,"abstract":"<p><p>The COVID-19 pandemic heightened health inequities among historically marginalized groups. Community-based and culturally responsive interventions, like the Natural Helper (NH) model, leverage trusted community members to impart health related information. The VaxUP! intervention sought to reach non-Hispanic Black and rural people living in Southwest Georgia by deploying NHs to address vaccine hesitancy and support vaccination. We recruited and trained 31 NHs to engage with their community and to make vaccine appointments. As part of the process evaluation, tracking forms that included closed- and open-ended questions were analyzed to understand NH activities. NHs reached over 1950 people and booked over 600 vaccine appointments. Most encounters occurred over the telephone and through one-on-one interactions. During the interactions, NHs discussed many COVID-19 related topics and most frequently discussed vaccination benefits and COVID-19 information. Through this intervention, NHs were able to engage their community in conversations about the COVID-19 vaccine and book appointments.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"60 Suppl 1 ","pages":"127587"},"PeriodicalIF":3.5,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144818879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}